Tividenofusp alfa (marketed as Avlayah) is an FDA-approved enzyme replacement therapy to treat the neurologic signs of Hunter syndrome (MPS II) in children.
Tividenofusp Alfa’s is a biologic medicine designed to cross the blood-brain barrier.
It helps children with Hunter syndrome, a rare genetic disorder.
It breaks down harmful sugar molecules called glycosaminoglycans (GAGs) in the brain and body.
It treats neurologic symptoms in pediatric patients.
Patients must weigh at least 5 kg (11 pounds).
Treatment should start before advanced brain or nerve damage happens.
Administered through an intravenous (IV) infusion, once a week.
The infusion takes about three to four hours.
Treatment begins with a slow dose increase in a clinic or hospital.
Common Side Effects
Infusion reactions (fever, chills, or rash during the drip) Upper respiratory infections Ear infections Vomiting and diarrhea Low red blood cells